Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

8.640 +0.160 (+1.89%)

Delayed Quote Updated: 1:24 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 Next >

Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 09, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

August 06, 2026

From Prothena Corporation plc

Via Business Wire

Prothena to Report Second Quarter 2026 Financial Results on August 6

July 30, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Reports First Quarter 2026 Financial Results and Business Highlights

May 07, 2026

From Prothena Corporation plc

Via Business Wire

Prothena to Report First Quarter 2026 Financial Results on May 7

April 30, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

April 27, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Announces Leadership Team Updates

April 10, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

March 21, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

March 09, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Announces up to $100 Million Share Repurchase Plan

February 27, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

February 19, 2026

From Prothena Corporation plc

Via Business Wire

Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

February 12, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Announces Board of Directors Update

December 12, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

November 19, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

November 11, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

November 06, 2025

From Prothena Corporation plc

Via Business Wire

Prothena to Report Third Quarter 2025 Financial Results on November 6

October 30, 2025

From Prothena Corporation plc

Via Business Wire

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease

October 01, 2025

From Prothena Corporation plc

Via Business Wire

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

August 28, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

August 27, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

August 06, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

August 04, 2025

From Prothena Corporation plc

Via Business Wire

Prothena to Report Second Quarter 2025 Financial Results on August 4

July 28, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Announces Corporate Restructuring

June 18, 2025

From Prothena Corporation plc

Via Business Wire

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

June 16, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

May 23, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

May 08, 2025

From Prothena Corporation plc

Via Business Wire

Prothena to Report First Quarter 2025 Financial Results on May 8

May 01, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

February 20, 2025

From Prothena Corporation plc

Via Business Wire

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

February 13, 2025

From Prothena Corporation plc

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.